A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, BIVV001, in Patients With Severe Hemophilia A (XTEND-1)

Phase 1

• Conditions: severe hemophilia A; MedDRA version: 20.0Level: PTClassification code 10016080Term: Factor VIII deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disorders; Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]

• Registration Number: EUCTR2019-002023-15-IT
• Lead Sponsor: BIOVERATIV THERAPEUTICS INC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-17
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 164

Inclusion Criteria

1. Participant, male or female, must be equal to or greater than 12 years of age inclusive, at the time of signing the informed consent.
2. Severe hemophilia A, defined as <1 IU/dL (<1%) endogenous FVIII activity as documented either by central laboratory testing at Screening or in historical medical records from a clinical laboratory demonstrating
<1% FVIII coagulant activity (FVIII:C) or a documented genotype known to produce severe hemophilia A
3. Previous treatment for hemophilia A (prophylaxis or on demand) with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 EDs.
4. Current regimen includes
• Prophylactic treatment regimen with a FVIII product or prophylactic emicizumab therapy for at least 6 months during the previous 12 months. Appropriate washout time needs to be taken into account.
• On-demand regimen with a FVIII product with a history of at least 12 bleeding episodes in the previous 12 months or at least 6 bleeding episodes in the previous 6 months prior to study enrollment. On-demand participant is accepting to move to a prophylaxis treatment regimen after 26-week on-demand period.
5. Willingness and ability of the participant or surrogate (a caregiver or a family member = or more than 18 years of age) to complete training in the use of the study electronic Patient Diary (ePD) and to use the ePD throughout the study.
6. Ability of the participant or his or her legally authorized representative (eg., parent or legal guardian) to understand the purpose
and risks of the study, willing and able to comply with study requirements and provide signed and dated informed consent or assent
(as applicable) and authorization to use protected health information in accordance with national and local participant privacy regulations.
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 149
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5

Exclusion Criteria

- Clinically significant liver disease.
- Serious active bacterial or viral infection (other than chronic hepatitis or HIV) present within 30 days of Screening.
- Other known coagulation disorder(s) in addition to hemophilia A.
- History of hypersensitivity or anaphylaxis associated with any FVIII product
- Positive inhibitor results, defined as = or above 0.6 BU/mL at Screening. History of a positive inhibitor test defined as = or above 0.6 BU/mL. Family history of inhibitors will not exclude the participant.
- Use of Emicizumab within the 20 weeks prior to Screening
- Major surgery within 8 weeks prior to Screening.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified